David J.A. Jenkins et al. JACC 2018;71:

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 A No. at risk T T T

Advertisements

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Mortality benefit from reduction in sodium consumption 1 Hypertension affects one-third of the US population, of which less than half have their blood.

Factorial Designs. Background Factorial designs are when different treatments are evaluated within the same randomised trial. A factorial design has a.

Calcium/Vitamin D-related CV Events Based on Poster 1163 “Risk of Cardiovascular Events with Calcium/Vitamin D – a Re-Analysis of the Women’s Health Initiative”

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Clinical Trials of Vitamin E Supplementation and Risk for All-Cause Mortality, Ordered by Dosage of.

What are supplements? A dietary supplement is intended to supplement the diet by providing nutrients that are missing or are inadequate in a person's.

Vitamin D Levels Predict All-Cause and Cardiovascular Disease Mortality in Subjects With the Metabolic Syndrome Featured Article: G. Neil Thomas, Ph.D.,

By: Ms. Guerra.  Oils are the major source of fatty acids that are necessary for health— called “essential fatty acids.”  Chocolate is a favorite.

Be Body Smart - Better, Naturally. Nutri-Smart - Better, Naturally 22 Vitamins and Minerals Whole Food Organic Phytonutrients Omega Fatty Acids Plant.

Journal Club Hallie Lee PharmD Candidate 2013 Mercer University COPHS PHA 618 Geriatrics-Continuous Care Multivitamins in the Prevention of Cardiovascular.

Mary Hannon-Fletcher Micronutrient supplementation in haemodialysis patient enhances folate levels and reduces homocysteine 4th Annual Translational Medicine.

Effect of Lowering the Glycemic Load With Canola Oil on Glycemic Control and Cardiovascular Risk Factors: A Randomized Controlled Trial Featured Article:

Modern Management of Cholesterol in the High-Risk Patient.

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Statins0.69 ( ) n=13 (16,228/11,279)

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Process of study selection F. Sofi, et al. BMJ 2008 Sep 11;337:a1344.

Hippisley-Cox J, Coupland C. Heart 2010;96:

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Vitamin D and Cardiovascular Disease: Will It Live.

The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.

The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.

Improvement of Apolipoprotein B in Argentine Indigenous School Children after Vitamin D Supplementation V. Hirschler, G. Maccallini, M. Hidalgo, M. Sanchez,

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

From: Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular DiseaseGrand Rounds Discussion From the Beth Israel Deaconess Medical.

Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation Jordi Bover,

SAVE: Risk of total mortality associated with reduced kidney function

David J.A. Jenkins et al. JACC 2018;71:

Baseline characteristics of HPS participants by prior diabetes

Trends in cardiovascular mortality in China, 2003–2013.

US Preventive Services Task Force. Ann Intern Med 2009;150:

Should We Use Antibiotic Prophylaxis for Flexible Cystoscopy

Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results

Association between highest tertile for homocysteine and mortality

Relative risk of major events with atenolol vs placebo

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

Martin Bødtker Mortensen, and Erling Falk JACC 2018;71:85-94

David J.A. Jenkins et al. JACC 2018;71:

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

David J.A. Jenkins et al. JACC 2018;71:

David J.A. Jenkins et al. JACC 2018;71:

Khurram Nasir et al. JACC 2015;66:

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis Eleanor J. Samarasekera, Julie M. Neilson, Richard.

Baseline Characteristics of the Subjects

Pamela E. Scott et al. JACC 2018;71:

The Mediterranean Diet, its Components, and Cardiovascular Disease

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Folic acid increases apical junctional pMLCK localization in vivo

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Zachary L. Steinberg et al. JACC 2017;69:

Zachary L. Steinberg et al. JACC 2017;69:

Increase of physical activity over time associated with lower HF risk

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Risk for cardiovascular disease and all-cause death according to RHR: (A) as categorical variable (HR≥75 bpm vs HR

David J.A. Jenkins et al. JACC 2018;71:

Kaplan-Meir survival plots for CHD mortality (A), CVD mortality (B), and all-cause mortality (C) in men grouped by TG/HDL-C ratio of 3.5. Kaplan-Meir survival.

David J.A. Jenkins et al. JACC 2018;71:

Forest plot illustrating the risk ratio of major bleeding

Comparison of conventional population-based, high-risk and motivational population-wide cardiovascular disease (CVD) prevention strategies. Comparison.

Percentage of total mortality cases from CHD, CVD, and other causes (A). Percentage of total mortality cases from CHD, CVD, and other causes (A). Mortality.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

David J.A. Jenkins et al. JACC 2018;71:

Trends in cardiovascular mortality in China, 2003–2013.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

QRISK 3 – Clare Hawley - Summary slide

Presentation transcript:

David J.A. Jenkins et al. JACC 2018;71:2570-2584 Supplemental Vitamins and Minerals: Micronutrient Risks and Benefits (A and B) Effects of commonly used vitamins and minerals and (C and D) vitamins with significant effects derived from summary plot estimates of risk ratios expressed as percentages. Popular supplements were without demonstrable effects on cardiovascular disease (CVD) or all-cause mortality. Both folic acid and B-vitamins showed benefits for stroke, whereas antioxidants and niacin showed a marginally significant increase in all-cause mortality. These data highlight the lack of effect of popular supplements on CVD and all-cause mortality but demonstrate potential benefits of folic acid supplementation for stroke. *Slow-release niacin with background statins. NNH = number needed to harm; NNT = number needed to treat. David J.A. Jenkins et al. JACC 2018;71:2570-2584 2018 The Authors